We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Loss of Long Noncoding RNA Inhibits Breast Tumor Metastasis in Mouse Model

By LabMedica International staff writers
Posted on 05 Jan 2016
Blocking the activity of a single long noncoding RNA (lncRNA) in malignant breast cancer mouse models transformed aggressive cancers into slow growing cyst-like tumors and reversed the metastatic process by up to 70%.

Long noncoding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides. More...
This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study.

Malat1 (metastasis-associated lung adenocarcinoma transcript 1) is among the most abundant lncRNAs whose expression is altered in numerous cancers. Investigators at Cold Spring Harbor Laboratory (NY, USA) examined the role of Malat1 in cancer by either knocking it out—genetically engineering animals to lack the Malat1 gene—or with specific antisense oligonucleotides (ASO) that blocked Malat1 activity despite the presence of the active gene.

They reported in the December 23, 2015, online edition of the journal Genes & Development that genetic loss or systemic knockdown of Malat1 using antisense oligonucleotides in the MMTV (mouse mammary tumor virus)-PyMT mouse mammary carcinoma model resulted in slower tumor growth accompanied by significant differentiation into cystic tumors and a reduction in metastasis by up to about 70%. The ASOs were developed in collaboration with the biotechnology firm Ionis Pharmaceuticals (Carlsbad, CA, USA).

Malat1 loss resulted in a reduction of branching morphogenesis in MMTV-PyMT- and Her2/neu-amplified tumor organoids, increased cell adhesion, and loss of migration. At the molecular level, Malat1 knockdown caused alterations in gene expression and changes in splicing patterns of genes involved in differentiation and pro-tumorigenic signaling pathways.

"We got an amazing result," said senior author Dr. David L. Spector, head of the gene regulation and cell proliferation program at Cold Spring Harbor Laboratory. "By removing Malat1—this one, single long noncoding RNA—we made a dramatic impact on the primary breast tumors in these mice. The tumors took on a wholly new character. Aggressive breast cancer tumors differentiated and took on cyst-like characteristics. They filled with fluid, which contained various proteins including milk proteins, demonstrating that some of the tumor cells had differentiated. Just as important, in these mice lacking Malat1, there was nearly no metastasis."

"We are very pleased and excited by this result," said Dr. Spector, "because it suggests that these metastatic tumors have a dependency on Malat1—they cannot thrive without it. And very importantly, targeting Malat1 should not have a deleterious effect on any normal cells. At least in this mouse model normal, noncancerous cells do not seem to care a bit if they have Malat1 or not. Only the cancer cells seem to require it."

Related Links:

Cold Spring Harbor Laboratory
Ionis Pharmaceuticals 



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.